Should you buy Celldex Therapeutics (CLDX)?
Updated
Strong technical momentum and an approximately 61% gap to analyst consensus create an asymmetric setup on paper, but four consecutive earnings misses and free cash flow that is deeply negative relative to revenue place business quality well below any investable threshold.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The stock has formed a golden cross, sits above all key moving averages with an RSI of 56 and bullish MACD, and shows sustained volume accumulation — a configuration consistent with continued upward price momentum in the near term. Momentum | Price trends toward the analyst consensus target; RSI holds in the 50–70 range and on-balance volume continues rising over the next two quarters. | →Stable |
| CounterMomentum in early-stage biotechs depends entirely on pipeline catalysts; without a positive clinical or partnership announcement, the entire technical pattern can reverse within days on a single headline. | ||
Analyst consensus implies roughly 61% upside from the current price of $32.12 to a target near $51.78, and a risk/reward ratio of approximately 8.7-to-1 in favor of the buyer is unusually wide for a name of this size. Price targets | Price closes at least half the gap to $51.78 within 12 months; consensus target holds or expands. | →Stable |
| CounterAnalyst price targets for pre-revenue biotechs regularly embed optimistic pipeline assumptions; a single failed trial could trigger a wave of target cuts that erases the apparent upside almost immediately. | ||
Free cash flow is deeply negative as a share of revenue, there is no recognizable competitive moat, and the financial strength score sits near the bottom of the range — characteristics that collectively place business quality well below the floor for a defensible long position. Quality | If the long-term thesis is intact, the company demonstrates improving cash efficiency and achieves at least one moat-building milestone — exclusivity, a licensing agreement, or positive phase data — over 12 months. | →Stable |
| CounterAccelerated spending on clinical development is rational at this stage; elevated cash consumption may reflect deliberate investment ahead of a value-inflecting readout rather than operational failure. | ||
The stock has formed a golden cross, sits above all key moving averages with an RSI of 56 and bullish MACD, and shows sustained volume accumulation — a configuration consistent with continued upward price momentum in the near term.
→Stable- Expectation
- Price trends toward the analyst consensus target; RSI holds in the 50–70 range and on-balance volume continues rising over the next two quarters.
CounterMomentum in early-stage biotechs depends entirely on pipeline catalysts; without a positive clinical or partnership announcement, the entire technical pattern can reverse within days on a single headline.
Analyst consensus implies roughly 61% upside from the current price of $32.12 to a target near $51.78, and a risk/reward ratio of approximately 8.7-to-1 in favor of the buyer is unusually wide for a name of this size.
→Stable- Expectation
- Price closes at least half the gap to $51.78 within 12 months; consensus target holds or expands.
CounterAnalyst price targets for pre-revenue biotechs regularly embed optimistic pipeline assumptions; a single failed trial could trigger a wave of target cuts that erases the apparent upside almost immediately.
Free cash flow is deeply negative as a share of revenue, there is no recognizable competitive moat, and the financial strength score sits near the bottom of the range — characteristics that collectively place business quality well below the floor for a defensible long position.
→Stable- Expectation
- If the long-term thesis is intact, the company demonstrates improving cash efficiency and achieves at least one moat-building milestone — exclusivity, a licensing agreement, or positive phase data — over 12 months.
CounterAccelerated spending on clinical development is rational at this stage; elevated cash consumption may reflect deliberate investment ahead of a value-inflecting readout rather than operational failure.
▸ Show 1 more pillar▾ Show fewer
The company has missed consensus EPS estimates in each of its four most recent reported quarters, with an average shortfall of roughly 10%, indicating that spending consistently runs ahead of analyst models.
→Stable- Expectation
- To resolve this concern, actual results must come in above estimates in at least two of the next four reporting periods.
CounterPre-commercial biotechs often invest aggressively ahead of pivotal trials; higher-than-modeled R&D expense during this window may represent rational capital allocation rather than poor execution discipline.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The stock has formed a golden cross, sits above all key moving averages with an RSI of 56 and bullish MACD, and shows sustained volume accumulation — a configuration consistent with continued upward price momentum in the near term.
Trip ifRSI falls below 40 for 2 consecutive weeks.
- P2Analyst consensus implies roughly 61% upside from the current price of $32.12 to a target near $51.78, and a risk/reward ratio of approximately 8.7-to-1 in favor of the buyer is unusually wide for a name of this size.
Trip ifAnalyst consensus price target compresses by more than 20% from its current $51.78 level within 12 months.
- P3Free cash flow is deeply negative as a share of revenue, there is no recognizable competitive moat, and the financial strength score sits near the bottom of the range — characteristics that collectively place business quality well below the floor for a defensible long position.
Trip ifFree cash flow rises above $0 for 2 consecutive reported quarters.
- P4The company has missed consensus EPS estimates in each of its four most recent reported quarters, with an average shortfall of roughly 10%, indicating that spending consistently runs ahead of analyst models.
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters.
How the engine reached this verdict
TrendMatrix's engine output for Celldex Therapeutics, Inc. (CLDX) is SELL_IF_HOLDING with medium conviction, score 5.2/10 at $35.29. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
On the bear side: Quality below floor (1.4 < 4.0). Active engine warnings: Quality below floor (1.4 < 4.0).
The engine's exit framework anchors to a tactical sell band near $35.29, with structural invalidation at $32.79. The asymmetric R:R against a reversal hypothesis is 6.70 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates CLDX — 10-dimension breakdown →
Bear case
- ▸Quality below floor (1.4 < 4.0)